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The process of scientiﬁc hypothesis formulation affects the experimental designs, methods and interpre-
tations applied, but to be testable, the hypotheses posed must conform to the state of scientiﬁc knowl-
edge and available technology. An analogous situation exists in risk assessment, where the questions
addressed are typically articulated in the problem formulation phase. Decades ago, regulatory agencies
couched problem formulation according to the questions answerable by the science of the day. As regu-
latory requirements for risk assessment became codiﬁed, so too did the rudiments of problem formula-
tion. Unfortunately, codifying problem formulation prevented it from evolving to keep pace with
scientiﬁc advancements. Today’s more advanced science is not always being used effectively and efﬁ-
ciently in risk assessment because the risk assessment problem formulation step still typically poses anti-
quated questions. Problem formulation needs to be improved so that modern science can inform risk
considerations. Based on recent developments in the Human Relevance Framework and using
well-studied example chemicals – chloroform and carbon tetrachloride – an approach is proposed for
focusing problem formulation on human-relevant hypotheses. We contend that modernizing problem
formulation in this way will make risk assessment more scientiﬁcally accurate, more practical, and more
relevant for protecting human health and the environment.
 2015 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction and problem statement
As all scientists recognize, the hypotheses addressed in a scien-
tiﬁc investigation inﬂuence the experimental design. In pharma-
cology and toxicology, experimental design determines from
which organs, tissues, or in vitro systems speciﬁc types of mea-
surements are made, as well as the conditions under which the
measurements are taken, (e.g., route and duration of administra-
tion), the necessary control groups, and a variety of other factors.
The experimental design also determines the methods used to
record and analyze the data and the context in which the results
are interpreted. Thus, the results obtained from a scientiﬁc investi-
gation are largely dependent upon the questions posed, i.e., the
process of hypothesis generation. Fig. 1a provides a simple concep-
tual diagram of this process.The questions asked in an experimental investigation are both
constrained and empowered by the methodologies and technolo-
gies available to address them. As knowledge and technology
improves, the hypotheses that can be addressed by experimental
science gain sophistication. In pharmacology, for example, X-ray
crystallography, computer-assisted molecular modeling, site-
directed mutagenesis, pharmacogenomics, bioinformatics, and
other technological advancements have expanded drug develop-
ment beyond the observational screening of natural products to
include targeted molecular design based on mechanisms of action
and conformational knowledge of receptor and enzyme active
sites. By taking advantage of advancements in technology, pharma-
cologists can now pose and answer questions far more relevant to
understanding and treating disease processes than was possible
just a few decades ago. In similar fashion, toxicological research
has shifted rapidly since the 1960s from a science able to focus
only on the descriptive characterization of adverse effects to one
capable of probing the mechanisms underlying them (Hodgson,
2012). Toxicological research is now focused, more than ever
before, on applying knowledge of potential modes of action
(MoAs) to predict the types of adverse effects possible, or
A B
Fig. 1. Logic sequence used for scientiﬁc investigations (A) versus for hazard
identiﬁcation and risk assessment (B).
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Meek et al., 2014a).
The importance of hypothesis generation and study design is
well recognized in experimental sciences, but these concepts are
less well appreciated as organizing principles in risk analysis
despite their critical role in determining how information is evalu-
ated and integrated to reach overall conclusions regarding hazard
and risk. As illustrated in Fig. 1b, toxicological risk assessment
employs a process analogous to experimental hypothesis testing
whereby the questions to be addressed are identiﬁed in an initial
step called ‘‘problem formulation.’’ Components of problem formu-
lation include determining the assessment objectives, deﬁning
endpoints to be evaluated, developing a conceptual model and
integrating these into the protocol that will guide the assessment
itself. Similar to experimental hypotheses, the questions posed in
problem formulation determine the data evaluated, which in turn
inﬂuences the methods used to analyze the data and the interpre-
tations drawn from those analyses.
Recognizing that the scientiﬁc quality and applicability of infor-
mation produced by risk assessment depends on the problem for-
mulation step, the U.S. National Academy of Sciences recently
recommended that problem formulation also include considera-
tion of the available risk mitigation strategies for exposures of con-
cern (NAS, 2009). Just as the available technology inﬂuences the
hypotheses that can be addressed in experimental sciences, the
NAS recommendations implicitly recognize that the available risk
mitigation technologies inﬂuence the problem formulation step
of risk characterization. The NAS recommendations also indicate
the need for problem formulation to involve a comparison of com-
peting or alternative hypotheses regarding how best to evaluate
potential risks and to mitigate potential risks, given the available
technologies and approaches.
Although the NAS recommendations encourage a moderniza-
tion of the risk characterization phase of risk assessment, the initial
step of risk assessment, hazard characterization (hazard identiﬁca-
tion and dose response analysis), has not been explicitly addressed.
For the most part, current processes used by regulatory agencies
for identifying chemical hazards are still focused on broad, qualita-
tive questions about chemical effects that occur up to the
Maximum Tolerated Dose (MTD), consistent with the scientiﬁc
methods developed when hazard identiﬁcation methods were
established and standardized for regulatory purposes nearly
40 years ago. To streamline the discussion here, human carcino-
genic risk assessment will be highlighted, but the conceptual prin-
ciples apply to all types of toxicological risk assessment, regardless
of the type or mechanism of toxicity.In its 1976 Interim Cancer Assessment Procedures (EPA, 1976),
the U.S. Environmental Protection Agency (EPA) considered a
two-step process with regard to the regulation of a potential car-
cinogen, the ﬁrst being the decision as to whether a particular sub-
stance poses a cancer risk. To decide that question, the Agency
speciﬁed that a substance would be considered a presumptive can-
cer risk when it causes a statistically signiﬁcant excess incidence of
benign or malignant tumors in humans or animals, and acknowl-
edged that in most instances, the evidence is limited to animal
studies. This approach still drives the determination of a cancer
hazard by the International Agency for Research on Cancer (IARC,
2006). In fact, many programs, including EPA’s Integrated Risk
Information System (IRIS), the National Toxicology Program
(NTP) Report on Carcinogens and IARC formulate the toxicological
problem (hypothesis) in very broad terms. For example, the cur-
rent NTP classiﬁcation criteria state that a chemical is reasonably
anticipated to be a human carcinogen based on ‘‘. . . sufﬁcient evi-
dence of carcinogenicity from studies in experimental animals, which
indicates there is an increased incidence of malignant and/or a combi-
nation of malignant and benign tumors (1) in multiple species or at
multiple tissue sites, or (2) by multiple routes of exposure, or (3) to
an unusual degree with regard to incidence, site, or type of tumor,
or age at onset, . . .’’ (NTP, 2015).
Problem formulations framed in this way allow focusing on a
default, surrogate test species rather than on the species of con-
cern. Furthermore, even though humans are the species of concern,
the conditions of human exposure to chemicals are not considered
explicitly in formulating the critical question for hazard character-
ization. The methods that logically follow from questions posed in
this way – lifelong exposure near the MTD – were developed to
enhance statistical power, but employed the overly simplistic,
and arguably demonstrably false, assumption that administration
of high doses of a chemical to maximize tumor incidence among
a small number of animals (e.g., 50 animals per treatment group)
is a scientiﬁcally valid substitute for using sufﬁcient group sizes
to detect low-incidence events from lower, environmentally rele-
vant chemical doses (Gaylor, 2005; Freedman and Zeisel, 1988).
The case can be made that such practices were excusable before
probative mechanistic studies and exposure modeling techniques
were available. However, modern experimental science continues
to reveal that those methods are largely, or in many cases, entirely
irrelevant for the risk assessment goal of quantifying human health
risk at environmentally relevant levels of exposures. To list just a
few of the reasons: lifetime administration of the MTD is typically
thousands to millions of times higher than environmental expo-
sures; toxic effects in rodents can be due to species-speciﬁc mech-
anisms; and cross species predictability may be poor even among
rodents (Freedman et al., 1996), much less between rodent and
humans (Goodman and Wilson, 1991; Freedman and Zeisel,
1988). Mechanisms operating at high doses may not be occurring
at lower, environmentally relevant doses, and detoxiﬁcation pro-
cesses operating at lower doses may be overwhelmed at higher
doses. Opportunities for DNA repair that are abundant at lower
doses may be lost as toxicity impairs normal cellular processes at
high doses.
Furthermore, were group sizes increased to 200 animals, nearly
all chemicals would be expected to produce cancer in some organ
or tissue in standard rodent carcinogenicity tests (Gaylor, 2005).
Rather than distinguishing between true rodent carcinogens and
non-carcinogens, these bioassays are simply failing to detect the
weaker carcinogens at the MTD with 50 animals per dose group
(Gaylor, 2005). Consequently, so-called rodent carcinogenicity
tests are more likely to identify the dose of a chemical at which
toxicity produces tumors secondary to the cascade of cell
damage-replication-repair rather than detecting chemicals with a
unique carcinogenic property (Goodman et al., 1991; Gaylor,
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at some dose (Gaylor, 2005). Because, as conducted, these tests
have little or no utility for identifying potential human carcino-
gens, Gaylor (2005) argues that the question to be asked is not
whether a chemical is a rodent carcinogen at the MTD, but rather,
what is the relationship between dose and cytotoxicity and/or MoA
that could produce an excess of tumors? Today, problems with the
traditional MTD approach could be avoided by using
kinetically-derived maximum doses (KMD) from short-term stud-
ies instead of, or along with, the MTD to select appropriate doses
for chronic studies (Saghir et al., 2012).
A coordinated, well-conceived methodology – the Key Event
Dose–Response Framework and Human Relevance Framework
(hereafter referred to as the HRF) – has been developed to enable
up to date knowledge of MoA to be incorporated into hazard char-
acterizations and risk assessments (Sonich-Mullin et al., 2001;
Meek et al., 2003; Holsapple et al., 2006; Julien et al., 2009). This
framework begins with the hazard identiﬁcation–carcinogenic
classiﬁcation of the IRIS, IARC, and NTP testing paradigm, and asks
for elucidation of the MoA for tumor production in the rodent spe-
cies. If the carcinogenic MoA can be deﬁned in the rodent test spe-
cies, the HRF then asks whether the MoA is relevant to humans.
Dose response and pharmacokinetics are considered, as well as
the possibility for the MoA to exhibit thresholds that must be
exceeded for the production of a carcinogenic effect (Boobis
et al., 2006).
The HRF provides an effective correction for hazard identiﬁca-
tion conclusions that lack human relevance, e.g., for inhibition of
the LH surge in female rats by atrazine, for kidney tumors in male
rats induced by D-limonene via 2a-microglobulin, and for identify-
ing modes of action that exhibit a threshold, which can render
human carcinogenicity impossible under typical environmental
conditions or reasonably foreseeable exposure scenarios, e.g., chlo-
roform ingestion as a byproduct of drinking water disinfection
(Meek et al., 2003; Julien et al., 2009). These successful applications
of the HRF demonstrate that modern toxicological methods can
supply biological understanding much more speciﬁc and more
directly relevant to human risk than usually follows from the ques-
tion posed by the outdated problem formulation step embedded in
the approaches of IRIS, The National Toxicology Program (NTP),
and IARC.
Paradoxically, the HRF is typically used to test the relevance and
validity of the outcome of the assessments in an ex post factoman-
ner rather than directly testing hypotheses about chemical effects
and their modes of action. IARC’s Preamble reveals that MoA infor-
mation is used to inform and perhaps to modify presumptions
about cancer risks in humans based on animal studies conducted
by traditional methods, i.e., at the MTD in rodents.
Although this association cannot establish that all agents that
cause cancer in experimental animals also cause cancer in
humans, it is biologically plausible that agents for which there
is sufﬁcient evidence of carcinogenicity in experimental ani-
mals (see Part B, Section 6b) also present a carcinogenic hazard
to humans. Accordingly, in the absence of additional scientiﬁc
information, these agents are considered to pose a carcinogenic
hazard to humans. Examples of additional scientiﬁc information
are data that demonstrate that a given agent causes cancer in
animals through a species-speciﬁc mechanism that does not
operate in humans or data that demonstrate that the mecha-
nism in experimental animals also operates in humans (see
Part B, Section 6).
[IARC, 2006]
When the weight of evidence (WoE) is sufﬁcient to establish the
MoA in animals, the HRF then asks whether the human relevance
of the MoA can be reasonably excluded on the basis of eitherfundamental, qualitative differences in the key events or quantita-
tive differences in either kinetic or dynamic factors between ani-
mals and humans (Boobis et al., 2006; Meek et al., 2014b). Even
when not excluded on qualitative or quantitative grounds, MoAs
that require exceeding a threshold can render the carcinogenic
classiﬁcation practically irrelevant when foreseeable human expo-
sures will not reach the threshold.
Given the capability of modern toxicological methods to pro-
vide biological understanding relevant to human health, the ques-
tion is raised whether there is any utility in furthering the ﬂawed
approach of developing assessments based on hypotheses of ques-
tionable relevance to human health, only to follow with further
research to determine the relevance of ﬁndings reached in
response to those hypotheses? Would it not be more logical and
much more efﬁcient to use modern toxicological methods and
knowledge from the outset to answer questions of direct relevance
to human health?2. Proposed solution
The NAS panel’s recent report on EPA’s IRIS discusses various
approaches for integrating evidence from mechanistic studies, ani-
mal experiments and human epidemiological investigations (NAS,
2014). The NAS recommendations emphasize the need to include
in the design of the assessment a plan for gathering, analyzing
and integrating mechanistic information and knowledge. To
achieve this, we propose that the problem formulation step for
human health assessments must utilize modern toxicological
knowledge and methods to formulate speciﬁc hypotheses about
human hazards and risks. This can be done by ensuring that (1)
the problem formulation phase includes the development of alter-
native potential hypotheses regarding toxicological effects and
their underlying modes of action, and (2) that the analysis and
assessment phase focuses on comparing those hypotheses by
WoE using modern toxicological methods and data. This approach
draws from the Hypothesis-Based WoE method developed by
Rhomberg et al. (2010, 2011, 2013) and draws from deﬁnitions
of, and principles for conducting, WoE evaluations (Rhomberg
et al., 2013; Borgert et al., 2011). Following from WoE methods
and from application of the HRF, our proposed process involves
the following steps:
1. Read review articles on the subject compound and formulate
initial hypotheses. The goal is to identify key issues and possible
MoAs that could inﬂuence the hazard to humans, and to formu-
late these as an initial set of alternative hypotheses.
2. Based on initial hypotheses, design a comprehensive literature
search that focuses on studies informative about the proposed
key events in general as well as the subject chemical and its
hypothesized MoAs.
3. Collect literature & evaluate for data quality & reliability as per
Borgert et al. (2011; Supplemental Material).
4. Evaluate the literature with respect to the proposed key events
and hypothesized MoAs. If necessary, revise the alternative
hypotheses and augment with additional literature searches.
5. For each hypothesis, develop an overall WoE as to whether the
data are inconsistent, consistent, or supportive of each key
event.
6. Compare the level of support for the alternative hypotheses and
develop a WoE narrative that reaches a conclusion, if possible,
as to which hypothesis is most supportable. The narrative
should touch on elements of the various hypotheses that might
be strongly supported, tenable but not well supported, unable
to be ruled out, or untenable (reviewed by Rhomberg et al.,
2013).
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for modernizing problem formulation using chloroform and carbon
tetrachloride as the examples. We have not sought to illustrate the
entire method but have focused on aspects newly proposed herein,
which is the formulation and comparison of human-relevant
hypotheses. All other aspects of the method listed above is in cur-
rent practice (Boobis et al., 2006, 2009; Meek et al., 2014a), includ-
ing the concept of comparing MoA hypotheses by the strength of
the supporting data (Meek et al., 2014b). Since regulatory
decision-making already relies on application of the HRF to chloro-
form, it serves as an example of how modernizing the problem for-
mulation step improves the clarity and efﬁciency of the risk
assessment process. Carbon tetrachloride serves as a test case to
show howmodernizing the problem formulation step allows direct
consideration of the best available toxicological knowledge
throughout the risk assessment process. We contend that this is
an improvement over the current practice in which modern toxico-
logical methods and data are considered only as a test of relevance
on the initial application of, what are arguably, outdated default
assumptions. We also propose criteria that could be helpful in
deciding whether a sufﬁcient level of support has been attained
for any particular hypothesis such that it should be considered
the hypothesis most consistent with the overall weight of the
evidence for a subject chemical.
In this regard, it is important to understand that our proposal to
modernize problem formulation does not entirely dispense with
the current default assumptions. Rather, our proposal involves
articulation of the current default assumptions as one of the
hypotheses to be examined. This hypothesis will then be compared
to one or more alternative human-relevant MoA hypotheses. When
the available data is insufﬁcient to clearly establish one of the com-
peting alternative hypotheses, then the traditional approach to
hazard identiﬁcation conducted by rodent testing at the MTD
and application of default assumptions may be warranted. This
modernization of the problem formulation step promotes applica-
tion of modern toxicological methods and analysis throughout the
risk assessment process rather than withholding them until after
an initial hazard characterization process is completed using out-
dated methodologies and understanding.Fig. 2. Current IARC/IRIS problem formulation leads to confusion regarding
chloroform carcinogenicity.3. Chloroform
Chloroform (CHCl3) is a drinking water disinfection byproduct
that is widely found in drinking water systems. Alternative disin-
fection processes that generate less chloroform are available, but
they generate other byproducts, some of which may be of greater
concern than chloroform. Experiments have reported that chloro-
form is carcinogenic in the liver and kidney of mice and in the kid-
ney of rats. These effects, which are produced only by bolus oral
gavage administration of high doses (in corn oil) near the MTD,
form the basis for IARC and IRIS carcinogenicity classiﬁcations of
chloroform as an animal carcinogen and possible human carcino-
gen (EPA, 2001; IARC, 1999b).
Those chloroform-induced rodent liver and kidney tumors,
however, exhibit speciﬁcity for species, strain, sex and tissues,
and show a marked dependence on route of administration and
dose. The carcinogenicity of chloroform has been investigated
extensively over the past three decades in long term animal bioas-
says, in vivo and in vitro mechanistic studies, pharmacokinetic
evaluations in both animal test species and humans, and epidemi-
ological studies. These investigations have elucidated many key
aspects of chloroform carcinogenicity, including the role of genetic
and cellular toxicity, hepatic and extra-hepatic oxidative and
reductive metabolism, isozyme-speciﬁcity of metabolism, depen-
dence of carcinogenicity on cellular damage and proliferation,dose–response characteristics of obligate underlying processes,
and the correlation of carcinogenicity with potential MoAs.
Several peer-reviewed publications and consensus panel reports
have used these ﬁndings to evaluate chloroform’s neoplastic MoA
and derive pharmacokinetic models to predict its dose–response
characteristics. The key events in chloroform’s carcinogenic MoA
progress as described in recent publications (Boobis et al., 2009;
Boobis, 2010).
The MoA for chloroform carcinogenicity is sufﬁciently well
understood to have served as a model dataset to demonstrate the
utility of the HRF for reﬁning carcinogenicity evaluations and to
improve their extrapolation to human risk assessment.
Chloroform is an example for which the MoA does not exclude
human relevance qualitatively or quantitatively, but instead dic-
tates a threshold that is higher than environmentally relevant
human exposure levels and below which cancer does not occur.
Rather than the default assumption of a linearized no-threshold
dose–response function for human carcinogenicity of chloroform,
a reference dose (RfD) has been derived (EPA, 2001) consistent
with the data below that at which sustained hepatic toxicity does
not occur, and hence, no carcinogenic effects would be predicted.
Comparing the human RfD of 0.01 lg/kg/day to the lower 95% con-
ﬁdence interval on the benchmark dose 10% (LED10) of 23 mg/kg/-
day modeled from the dose response data for animal tumors
provides yields a margin of exposure of 2000. Maximum estimated
human exposures from persons living in dwellings supplied by
water with relatively high chloroform concentrations do not
exceed the RfD. In practical terms, therefore, chloroform is not a
possible human carcinogen under plausible human exposure sce-
narios. Even though the biochemical steps by which chloroform
induces tumors can occur in humans, its MoA renders tumor for-
mation impossible under any foreseeable consumer exposure
resulting from its presence in ﬁnished drinking water.
The typical approach for hazard characterization that is cur-
rently employed by many organizations relegates the considera-
tion of MoA to a separate step that occurs toward the end of an
assessment. This process is confusing and inefﬁcient, and can lead
to a situation whereby the human carcinogenicity of a chemical is
ﬁrst declared to be ‘‘possible’’ based on consideration of hazard
data and default assumptions, only to be declared ‘‘not possible’’
following application of the HRF using modern toxicological data
(Fig. 2). This confusion would be avoided and the process stream-
lined by posing alternative hypotheses in the problem formulation
step and testing them directly against all available, relevant and
reliable toxicological and toxicokinetic data (Fig. 3). Using this
method, four alternative hypotheses would need to be considered
for chloroform:
Fig. 3. Proposed problem formulation based on hypothesis testing and modern
toxicological data.
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human exposure levels arising from presence in ﬁnished
drinking water because it is oncogenic by a genotoxic mecha-
nism that operates at all dose levels. Expectations consistent
with this hypothesis would include compelling evidence of
genotoxicity in a variety of assays, particularly in vivo; lack
of a clear threshold for genotoxicity or tumorigenicity; an
increase in tumor incidence with increasing total dose in tar-
get tissues; and, evidence that humans are exposed to the
chemical.
2. Chloroform is unlikely to be a human carcinogen at foreseeable
human exposure levels arising from presence in ﬁnished drink-
ing water because it is oncogenic by a genotoxic mechanism
that operates only at doses greater than a humanmight foresee-
ably receive. Expectations consistent with this hypothesis
would include compelling evidence of genotoxicity above a crit-
ical concentration or dose, which would be strengthened by evi-
dence that either metabolism to a reactive metabolite also
occurs above the critical concentration or that detoxiﬁcation
is saturated above the critical concentration; that tumor inci-
dence corresponds with genotoxicity in target tissues above
the critical dose; and, that human exposures cannot foreseeably
produce the critical dose.
3. Chloroform is a possible human carcinogen at foreseeable
human exposure levels arising from presence in ﬁnished drink-
ing water because it is oncogenic by a cytotoxic mechanism that
operates at all dose levels. Expectations consistent with this
hypothesis would include negative genotoxicity data; lack of a
clear threshold for cytotoxicity or tumorigenicity, which would
be strengthened by demonstrated lack of detoxiﬁcation capac-
ity at low doses; correlation between tumor incidence and cyto-
toxicity at all doses; and, evidence that humans are exposed to
the chemical.
4. Chloroform is unlikely to be a human carcinogen at foresee-
able human exposure levels arising from presence in ﬁnished
drinking water because it is oncogenic by a cytotoxic mecha-
nism that operates only at doses greater than a human might
foreseeably receive. Expectations consistent with this hypoth-
esis include a preponderance of negative genotoxicity data;
clear evidence of a cytotoxic threshold in target tissues, which
would be strengthened by evidence of reparable toxicity at
lower doses proceeding to irreparable cytotoxicity at higher
doses; clear evidence of a critical dose required for tumor pro-
duction; and, that human exposures cannot foreseeably pro-
duce the critical dose.
A brief review of data on chloroform’s MoA illustrates how
these hypotheses can be compared.3.1. Absorption and distribution of chloroform to target tissue(s)
Chloroform is a low molecular weight, lipid soluble compound
and as such, it is well absorbed via most routes of exposure, partic-
ularly inhalation and ingestion, with rapid and extensive distribu-
tion to all tissues of the body (Boobis et al., 2009). Dosage
determines the relationships between systemic chloroform levels,
its distribution into fat, and its rate of systemic elimination. The
elimination of chloroform appears to be saturable, increasing sys-
temic and target organ exposures disproportionately at higher
doses. Accumulation in fat is likely not to be saturable, and
although the mechanisms are unknown, elimination may be
enhanced by repeated, lower level exposures (Boobis et al.,
2009). Given the physical chemical properties of chloroform, its
absorption and distribution would be similar by inhalation, inges-
tion and dermal routes, differing only in kinetics.
A number of physiologically-based pharmacokinetic/pharmaco
dynamic (PB-PK/PD) models have been developed (Corley et al.,
2000; Delic et al., 2000; Luke et al., 2010; Krishnan and Johanson,
2005; Lévesque et al., 2002; Liao et al., 2007; Reitz et al., 1990;
Tan et al., 2003, 2006). One of the earliest and most cited of these
studies (Corley et al., 2000) developed a PB-PK/PD model based on
measured chloroform in the exhaled breath of male and female
volunteers exposed via bathwater at two temperatures, 35 and
40 C. Compared to ingestion of water at the same concentration,
dermal exposures were estimated to potentially contribute 1–
28% of daily chloroform, dependent on the water temperature
and the gender of the subject (males absorbed more chloroform
than females from 35 C water).
The toxicological targets of chloroform – liver and kidney – are
identical by dermal, inhalation and oral exposure routes. However,
chloroform in drinking water fails to induce tumors at daily doses
greater than those that produce tumors when given by gavage.
Since both methods of administration involve absorption via the
gastrointestinal tract, the possible differences would relate only
to the vehicle (corn oil versus water) and time-frame of adminis-
tration. Administration by gavage in corn oil delivers chloroform
to the target organs in bolus fashion whereas drinking water dis-
tributes the dose over the duration of drinking each day. Unless a
threshold existed for bioactivation of chloroform to a mutagenic
metabolite, there would be no reason that a mutagenic MoA would
exhibit this profound difference with time-frame of administra-
tion, nor is any mechanism known whereby corn oil would alter
metabolism of chloroform. Hence, the absorption and distribution
kinetics of chloroform assist in distinguishing among the four
alternative hypotheses regarding carcinogenicity, strongly sup-
porting hypotheses that rely on a threshold and substantially
weakening those that do not. Furthermore, this profound differ-
ence in tumorigenicity favors a mechanism that does not rely on
damage to DNA.
3.2. Oxidative metabolism of chloroform to highly reactive phosgene
by the P450 enzyme CYP2E1
Chronic bioassays conducted by oral and inhalation routes
demonstrate that cytotoxicity and tumor induction depend on
the level of tissue CYP2E1 activity and secondarily on levels of
anti-oxidants and free radical scavengers such as glutathione
(Meek et al., 2002); these relationships do not differ by route of
exposure. Although skin and lung possess CYP2E, these tissues
have lower activity of the enzyme and have not been shown to
be sites of tumor induction. CYP enzymes are highly conserved
between rodents and humans, and a single gene is the source of
CYP2E1 in human and rodent tissues, including liver, lung and skin
(Neis et al., 2010; Baron et al., 2008; Du et al., 2004;
Ingelman-Sundberg, 2004). This limits the potential for large
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exposure. Thus, there are no data to suggest a difference in chloro-
form’s MoA for tumor induction between oral, dermal or inhalation
exposure.
Boobis et al. (2009), Boobis (2010) describe several lines of evi-
dence implicating CYP2E1 in chloroform carcinogenicity. Chief
among these includes counterfactual experiments conducted in
CYP2E1-knockout mice. Counterfactual experiments test whether
the effect of interest still occurs when a putative causal step is pre-
vented under conditions that would otherwise produce the effect
of interest. In CYP2E1 knock-out mice, chloroform does not cause
hepatic or renal necrosis, nor is there found any evidence of regen-
erative proliferation or increased mitotic indices (Boobis et al.,
2009; Boobis, 2010; Constan et al., 1999). Because of its highly con-
served character and the fact that a single isoform prevails in all
species other than rabbit (Boobis et al., 2009; Boobis, 2010), this
experimental system unequivocally demonstrates the obligate role
of CYP2E1 in chloroform carcinogenicity in mice and strongly sug-
gests that its role is generalizable to other species. Corroborative
evidence is provided from normal mice and in rats, in which
CYP2E1 expression levels within and among tissues correlates well
with the extent of chloroform toxicity (Boobis et al., 2009; Boobis,
2010). The tissues most affected are kidney and liver. Metabolic
conversion of chloroform to phosgene follows classic Michaelis–
Menton kinetics, with no threshold for substrate conversion. The
kinetics of conversion are linear up to substrate concentrations
that support approximately 70% of the Vmax for CYP2E1, at which
point the rate of conversion begins to plateau (Boobis, 2010).
CYP2E1-mediated oxidative metabolism of chloroform to phos-
gene is not itself a threshold process, and does not alone help to
distinguish the alternative hypotheses regarding human carcino-
genicity of chloroform. However, its obligate role in chloroform
metabolism and toxicity, as demonstrated by counterfactual
experimentation, would ensure that subsequent key events are
thresholded and precludes other pathways that would otherwise
not be expected to exhibit a threshold. Phosgene is a highly reac-
tive electrophile that reacts rapidly to form covalent bonds with
intracellular nucleophiles such as glutathione, proteins, lipids and
other macromolecules. As a result, phosgene cannot diffuse far
from its site of production in mitochondria and the endoplasmic
reticulum. This limits its potential molecular targets to those orga-
nelles and renders interaction with DNA in the nucleus highly unli-
kely, if not impossible. Conversion to phosgene as an obligate event
in chloroform toxicity is thus consistent with the lack of evidence
for chloroform-induced DNA damage in vivo.
Although phosgene is produced following absorption of even
the lowest doses of chloroform, phosgene reactivity with func-
tional and structural macromolecules appears to be limited – and
is likely to be totally prevented at low concentrations – by intracel-
lular pools of glutathione and other free radical scavengers. Thus,
these cellular defenses against oxidative damage likely contribute
to the apparent threshold for chloroform toxicity and carcinogene-
sis observed in rodent bioassays. Signiﬁcant toxicity would not be
expected until phosgene production is sufﬁcient to markedly
deplete intracellular pools of these protective molecules and
exceed the considerable ability of cells to rapidly replenish them
(Boobis, 2010; Boobis et al., 2009). This is consistent with the fact
that chloroform toxicity is observed only in the organelles of cells
that express CYP2E1, and the corresponding tissues and organs.
Evidence for reductive metabolism of chloroform suggests that
if it occurs at all, it occurs at doses that have already saturated
oxidative metabolism in rodents and humans, and above those
doses that produce liver and kidney tumors in rodents (Gemma
et al., 2003; Meek et al., 2002; Golden et al., 1997), which are them-
selves far greater than potential human environmental or indus-
trial exposures. Therefore, reductive metabolism of chloroform isnot physiologically relevant to the carcinogenic mechanism, even
though it may occur under some experimental conditions. Thus,
the details of chloroform metabolism and its relationship to toxic-
ity and tumorigenicity support hypotheses that do not depend on
DNA-damage and weakens those that do.
3.3. Lack of chloroform genotoxicity
A number of in vitro and in vivo studies have been performed to
evaluate the mutagenicity of chloroform. The preponderance of
these studies are negative, indicating no potential for chloroform
to be carcinogenic via damage to DNA. Although it is beyond our
scope to review this body of literature, it is important to note that
many of the studies that produced positive results were poorly
designed, confounded, poorly reported, or produced data of rela-
tively low quality. EPA has summarized those concerns, including
the importance of systems with internal metabolic activation
capacity, avoidance of cytotoxic levels that can confound results,
and use of solvents or preservatives that can react to form potent
alkylating agents that would not occur in intact organisms.
Consequently, although some positive results for genotoxicity have
been reported with chloroform, these are generally of questionable
relevance and/or used cytotoxic concentrations, some above the
LD50 for chloroform (EPA, 2001).
Using a published, comprehensive, quantitative WoE approach
to evaluate large, heterogeneous genetic toxicology databases,
chloroform’s potential mutagenicity was assessed by an expert
panel. On a scale of 100 to 100, chloroform scored 14.3, indicat-
ing that theWoE supports a non-genotoxic classiﬁcation (Andersen
et al., 2000). Regarding conﬂicting data, Andersen et al. (2000)
point out ‘‘[T]he fact that a compound causes genotoxicity under some
limited set of experimental conditions does not necessarily mean that
carcinogenic effects of the compound would be related to mutagenic-
ity.’’ Boobis (2010) notes that chloroform is generally negative in
tests for genotoxicity both in vitro and in vivo, concluding that
‘‘. . .the weight of evidence is that genotoxicity is not the MoA for chlo-
roform.’’ These analyses weaken hypotheses that rely on DNA dam-
age, mutations, or other genotoxic events to mediate a
carcinogenic effect of chloroform.
3.4. Requirement for sustained chloroform-induced cytotoxicity in
target cells, hepatocytes and/or renal proximal tubular epithelial cells
Phosgene reacts rapidly and covalently with structural and
functional macromolecules near its site of production. Although
the exact mechanism of cell death is not well understood, these
covalent interactions interrupt mitochondrial integrity, reduce cel-
lular energy production, and collapse membrane permeability
transition pores (Boobis, 2010; Boobis et al., 2009). When this
damage reaches a sufﬁcient level, membrane permeability is lost,
which is the determining factor in cell death. However, because
mitochondria can tolerate some level of insult without any change
in membrane permeability, and can repair low-level damage, they
would be resilient to low level phosgene production. Mitochondrial
resilience and repair is demonstrable in both rodents and humans
(Boobis, 2010; Boobis et al., 2009) and well explains the observed
recovery from low level cytotoxicity following low doses of chloro-
form. Higher doses of chloroform, sustained for periods of time suf-
ﬁcient to exceed mitochondrial tolerance to damage and repair
capacity, result in cell death and tissue necrosis in liver and kidney.
In vitro and in vivo evidence clearly indicate that chloroform
cytotoxicity and cell death exhibit a threshold in both liver and
kidney (Boobis, 2010; Boobis et al., 2009). Together with the lack
of chloroform toxicity in tissues that do not express CYP2E1, these
facts strongly indicate that sustained phosgene-induced cytotoxic-
ity is a key event in chloroform-induced carcinogenesis. It is
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Fig. 4. Conceptual illustration of chloroform pharmacokinetics following adminis-
tration by oral gavage ( ), drinking water ( ) and inhalation
( ) routes relative to concentrations that produce regenerative hepatic
hyperplasia.
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data since molecular damage to DNA in target organs should
increase progressively with increasing production of reactive
metabolites, i.e., phosgene, producing a progressive increase in
tumor incidence with dose. Consequently, these data further
weaken hypotheses for chloroform carcinogenicity involving
mutagenicity, but strongly support hypotheses that require sus-
taining a cytotoxic threshold dose in liver and kidney that over-
whelms the cellular capacity to protect against oxidative damage
from phosgene.
3.5. Requirement for chloroform-induced regenerative cell
proliferation in liver and/or kidney
When toxicity results in signiﬁcant cell death, the surviving
cells of many tissues may respond with compensatory prolifera-
tion. Except when toxicity and cell death are so severe that no
viable cells remain, compensatory proliferation regenerates cell
numbers, lost tissue, organ function, and functional reserve in both
liver and kidney. Compensatory proliferation is counterbalanced
by apoptosis so that the overall extent of tissue growth does not
exceed the amount necessary to restore functional capacity and
reserve. Because both liver and kidney have sufﬁcient functional
reserve to tolerate a small amount of damage without the need
for compensatory proliferation, there is a level of cell death in
these organs below which the proliferative, compensatory
response is not observed. Bromodeoxyuridine (BrdU) labeling
experiments in both mice and rats have demonstrated doses and
durations of chloroform administration below which no increase
in proliferation is observable in liver or kidney (Boobis et al.,
2009). Induction of the proliferative response is dependent upon
sufﬁciency of both dose and duration of exposure. Moreover, at
doses/durations sufﬁciently cytotoxic to induce the compensatory
response, proliferation is reversible and returns to baseline soon
after cessation of dosing.
Measurement of cell proliferation is one of the most precise,
quantitative and reproducible of cellular measurements, greatly
exceeding the precision of tumor dose response assessments from
2-year bioassays and some other measures of cell toxicity such as
histopathology (Butterworth and Bogdanffy, 1999). Precise quanti-
tation makes possible accurate delineation of doses and durations
of chloroform exposure that do not induce, versus those that do
induce, cell proliferation. Prolonged cell proliferation is critical
for the production and selection of pre-neoplastic cells, which
can enter the neoplastic progression to cancer. Under normal cir-
cumstances, however, cellular and tissue defense mechanisms,
including apoptosis, expunge altered cells, exerting a negative
selection pressure that aborts neoplastic progression.
Chloroform exposures sufﬁcient to elicit cytotoxicity, cell death,
and a compensatory proliferative response in liver and/or kidney
have been demonstrated to produce altered cells that can lead to
cancer in those organs, but only when the exposure is sufﬁciently
prolonged to allow selection and clonal expansion of altered cells.
Otherwise, cells altered during the proliferative response are efﬁ-
ciently eliminated once exposure has ceased. Because proliferation
is the event that leads to selection or production of pre-neoplastic
cells necessary for the neoplastic progression to cancer, these phe-
nomena provide further mechanistic explanation for the observed
threshold in chloroform toxicity and carcinogenicity. On the con-
trary, there would appear to be no evidence that chloroform
directly stimulates hyperplasia, inhibits apoptosis, or activates
receptors involved in cell proliferation at tumorigenic doses,
including hormone receptors, making it highly unlikely that
growth stimulation is involved in chloroform’s MoA (Boobis, 2010).
These characteristics of chloroform-induced tumors are incon-
sistent with no-threshold hypotheses of carcinogenic action.Mutagenic mechanisms would be expected to produce DNA dam-
age and increase tumor incidence in target organs at any level of
chloroform that produces reactive metabolites, i.e., at all doses,
yet this is clearly not observed. Furthermore, since conversion of
chloroform to reactive phosgene increases with increasing chloro-
form blood concentrations, a mutagenic mechanism cannot be rec-
onciled with the observation that chloroform tumorigenesis occurs
following bolus gavage administration, but not with higher doses
administered in drinking water which produce a greater area
under the chloroform blood concentration curve. Here, pharma-
cokinetic differences between bolus gavage and drinking water
dosing reproduce the tumorigenic conditions without producing
cytotoxicity or sustained regenerative hyperplasia (Fig. 4), thus
constituting a counterfactual demonstration of the necessity of
these events. Similarly, cytotoxic mechanisms that lack a threshold
would be expected to increase tumor incidence at all chloroform
doses at which cytotoxicity is measurable. This is also not
observed. Instead, chloroform tumorigenesis requires dosing sufﬁ-
cient to sustain a cytotoxic effect in kidney and/or liver. These
observations argue strongly for a cytotoxic, threshold mechanism
of chloroform carcinogenesis and preclude non-threshold mecha-
nisms that might occur by either mutagenesis or cytotoxicity.
The requirements for tumorigenesis in rodents have been found
to be a sufﬁcient level of chloroform and consequent metabolism
to phosgene to produce chronic cytotoxicity and compensatory
regenerative hyperplasia. Although the proliferative and damage–
repair processes in humans may differ quantitatively from those
in rodents (humans generally have more robust repair capacity),
they are qualitatively similar. Hence, the same processes that can
lead to liver and kidney cancer in rodents are possible in humans,
and although humans may exhibit different thresholds of dose and
duration, the qualitative similarity of the overall processes are suf-
ﬁcient to expect thresholds for chloroform carcinogenicity in
humans as has been demonstrated in rodents (e.g., Boobis, 2010;
Boobis et al., 2009).
3.6. Correlation of high-dose chloroform sustained cytotoxicity and
regenerative proliferation with production of tumors in liver and/or
kidney
Chloroform doses and dosing regimens that result in cytotoxic-
ity and regenerative cell proliferation induce liver cancer in male
and female B6C3F1 mice; kidney cancer in male, but not female,
BDF1 mice; and kidney cancer in male, but not female,
Osborne-Mendel rats. No tumors were induced in either male or
female Fischer-344 rats (Butterworth and Bogdanffy, 1999). No
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cytotoxicity and regenerative proliferation.
For CHCl3, the panel agreed unanimously that a mode of action
involving obligatory cytotoxicity as a precursor to cancer in tar-
get tissues was most plausible, i.e., much more strongly sup-
ported by the comprehensive data set than any of the other
modes of action. To paraphrase the conclusion, there should
be no signiﬁcant carcinogenic risk from CHCl3 at concentrations
below those that cause cell damage.
[Andersen et al., 2000]The most plausible explanation for the fact that chloroform
administered in drinking water fails to induce tumors at daily
doses greater than those that produce tumors when given by gav-
age is the pharmacokinetic difference in peak dose, which exceeds
the ability of cells to protect against cytotoxicity by bolus gavage
but not by divided oral doses (Butterworth et al., 1995a,b;
Conolly and Butterworth, 1995). A pharmacokinetic explanation
is consistent with data indicating that the threshold for sustained
cytotoxicity and proliferative regeneration matches the observed
threshold for tumorigenic response.
Butterworth et al. (1995b) compared predictions of the lin-
earized multistage model for hepatocellular carcinoma incidence
in female mice administered chloroform by gavage to predictions
of the dose–response model based on cell proliferation for tumor
incidence in female mice administered chloroform in drinking
water. Clearly, the cell proliferation model and not the LMS model
agreed with actual data. This indicates that the alternative hypoth-
esis – that chloroform carcinogenesis proceeds via a MoA that lacks
a threshold – fails to account for the observed data as well as the
observation that chloroform carcinogenicity proceeds via a cyto-
toxic mechanism operable only at high doses.
Melnick et al. (1998), Cofﬁn et al. (2000) demonstrated a lack of
consistency between cytotoxicity, regenerative hyperplasia and
tumor formation in B6C3F1 mouse liver among trihalomethanes,
but those data do not refute other studies showing that cytotoxic-
ity is required but insufﬁcient speciﬁcally for chloroform-induced
liver tumor formation; the key event in chloroform’s MoA is sus-
tained cytotoxicity that induces regenerative hyperplasia. Low
levels of liver toxicity are apparently tolerated and repairedTable 1
Comparison of support for hypotheses regarding chloroform carcinogenicity.
Key Events in the animal MoA Hypothesis 1
Possible human carcinogen at
foreseeable exposures by
genotoxic MoA at all exposure
levels
Hypothe
Unlikely
carcinoge
exposure
threshold
Absorption and distribution of
chloroform to target tissue(s)
Consistent Consisten
Oxidative metabolism of chloroform to
highly reactive phosgene by the P450
enzyme CYP2E1
Consistent Consisten
Lack of chloroform genotoxicity Inconsistent Inconsist
Requirement for sustained chloroform
cytotoxicity in target cells,
hepatocytes and/or renal proximal
tubular epithelial cells
Inconsistent Consisten
Requirement for chloroform-induced
regenerative cell proliferation in liver
and/or kidney
Inconsistent Consisten
Correlation of high-dose sustained
cytotoxicity and regenerative
proliferations with production of
tumors in liver and/or kidney
Inconsistent Consisten
* This step is strongly supported by the counterfactual demonstration of tumorigenicwithout induction of regenerative hyperplasia and tumor forma-
tion (Boobis, 2010; Boobis et al., 2009).3.7. Evidence integration: WoE conclusion for chloroform carcinogenic
hazard
As several comprehensive publications have explained the WoE
for chloroform’s carcinogenic MoA, the details will not be repeated
here. However, when problem formulation is conducted with
human relevant questions as alternative hypotheses, as proposed
here, the results of the WoE conclusion are much more clear and
understandable (Table 1). Consistent with the conclusions of other
publications, the only hypothesis strongly supported by the avail-
able data is Hypothesis 4, i.e., that chloroform is not a human car-
cinogenic hazard at foreseeable human exposure levels, where
cytotoxicity does not occur. Other hypotheses, particularly
hypotheses 1 and 3, are sufﬁciently inconsistent with the available
data that they should be considered as refuted.
It might be speculated, principally on the foundation that a neg-
ative conclusion is unprovable, that Hypothesis 2 cannot be
excluded, i.e., that a genotoxic MoA contributes to chloroform car-
cinogenicity as a consequence of cytotoxicity. Theoretically, geno-
toxicity could occur and contribute to tumorigenicity at tissue
concentrations above those that saturate cellular protections
against oxidative damage as well as saturate available lipid and
macromolecular targets in cellular organelles. However, this would
nonetheless be a thresholded process indistinguishable from the
cytotoxic pathway that is primarily responsible for
chloroform-induced rodent tumors. Thus, a high-dose genotoxic
threshold mechanism seems an irrelevant speculation that
nonetheless leads to the conclusion that chloroform presents no
carcinogenic hazard to humans at does below the threshold.
Finally, speculation could be raised that the hazard identiﬁca-
tion of chloroform according to hypothesis 4 – unlikely to be a
human carcinogen from use of chlorine in disinfection of drinking
water – is dependent on exposure assumptions that could be
exceeded under some scenarios, for example, from inhalation
exposure during strenuous swimming from use of chlorine to dis-
infect swimming pool water. Such speculation could be addressed
in the problem formulation phase by a separate hypothesis.sis 2
human
n at foreseeable
s by genotoxic,
ed MoA
Hypothesis 3
Possible human carcinogen at
foreseeable exposures by
cytotoxic MoA at all exposure
levels
Hypothesis 4
Unlikely human
carcinogen at foreseeable
exposures by cytotoxic,
thresholded MoA
t Consistent Consistent
t Consistent Consistent
ent Consistent Consistent
t Inconsistent Supportive
t Inconsistent *Supportive
t Inconsistent Supportive
doses in drinking water failing to produce cancer.
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chloroform as there is an order of magnitude safety factor for
human inhalation exposure to chloroform above the mouse inhala-
tion NOAEL for liver hyperplasia of 10 ppm chloroform in air
(Constan et al., 2002). Consequently, additional safety factors for
protection of human health are unnecessary (Constan et al.,
2002). Furthermore, it is important to recognize that this margin
of safety is exceptionally large because it applies not to single
exposures but to the repeated, daily exposures needed to induce
sufﬁcient hepatotoxicity to lead to regenerative hyperplasia. As
discussed by Constan et al. (2002), this large margin of safety is
consistent with the fact that only a single instance of liver toxicity
was reported from use of chloroform as an anesthetic at concentra-
tions greater than 22,000 ppm for periods of 30 minutes to 2 hours,
and children did not appear to be more sensitive than adults in this
regard.
4. Carbon tetrachloride
Carbon tetrachloride (CCl4) is a solvent that has been used as a
dry-cleaning agent, fabric-spotting ﬂuid, reagent in chemical syn-
thesis, ﬁre extinguisher ﬂuid, grain fumigant, and in the production
of chloroﬂourocarbon (CFC) refrigerants. Use of carbon tetrachlo-
ride has declined since the 1970s, when the Consumer Product
Safety Commission banned its use in consumer products and
restrictions on the use of CFCs increased (EPA, 2010; Eastmond,
2008).
Like chloroform, carbon tetrachloride has been designated a
possible human carcinogen by the U.S. EPA (2010) and by IARC
(1999a), based on production of hepatocellular carcinomas and
adenomas in rodents by oral, inhalation and parenteral exposures
when administered hepatotoxic doses. Carbon tetrachloride hepa-
totoxicity has been extensively researched and is considered a
model for understanding toxicological responses of the liver. Also
like chloroform, this extensive research has identiﬁed obligate
key events in the carcinogenic MoA of carbon tetrachloride.
Although additional details about the precise mechanisms under-
lying these key events may be learned with more research, the
available data strongly support a cytotoxic MoA that does not oper-
ate until a dose is received sufﬁcient to cause sustained hepatocel-
lular damage and regenerative proliferation (Manibusan et al.,
2007; Eastmond, 2008; Meek et al., 2014b). Sections 3.1–3.6 reﬂect
the consensus MoA for carbon tetrachloride, using the terminology
of Manibusan et al. (2007).
In a recent EPA IRIS assessment, EPA determined that the car-
cinogenic risks from carbon tetrachloride should be determined
using a linear, non-threshold model. In reaching that conclusion,
EPA elevated the default hypothesis and assumptions to a level
that essentially required disproving the hypothesis before accept-
ing an alternative hypothesis. Such an approach produces a conclu-
sion that is inconsistent with the extensive body of evidence and
scientiﬁc understanding of the carcinogenic MoA in rodent liver.
In addition, this requirement to ‘‘disprove the default hypothesis’’
is inconsistent with the scientiﬁc method because the default
hypothesis is not grounded on data, but on unveriﬁed assumptions.
In essence, it is impossible to disprove conclusions that are based
on belief rather than data. This is a clear example of the need for
modernizing problem formulation and illustrates the inefﬁciency
of the current process. When the default assumptions of
mid-20th century toxicology are inconsistent with modern toxico-
logical understanding, considerable time and resources are
required to challenge the relevance of the MoA for humans using
modern toxicological methods before questions of direct relevance
to human hazard can be addressed.
As proposed for chloroform, our modernization of the problem
formulation step indicates that four alternative hypotheses wouldneed to be considered for carbon tetrachloride. Expectations con-
sistent with these hypotheses are the same as for the respective
hypotheses involving chloroform, explained above.
1. Carbon tetrachloride is a possible human carcinogen at foresee-
able human exposure levels because it is oncogenic by a geno-
toxic mechanism that operates at all dose levels.
2. Carbon tetrachloride is unlikely to be a human carcinogen at
foreseeable human exposure levels because it is oncogenic by
a genotoxic mechanism that operates only at dose levels greater
than those humans might foreseeably receive.
3. Carbon tetrachloride is a possible human carcinogen at foresee-
able human exposure levels because it is oncogenic by a cyto-
toxic mechanism that operates at all dose levels.
4. Carbon tetrachloride is unlikely to be a human carcinogen at
foreseeable human exposure levels because it is oncogenic by
a cytotoxic mechanism that operates only at dose levels greater
than those humans might foreseeably receive.
4.1. Absorption and distribution of carbon tetrachloride to the liver
(target tissue)
Carbon tetrachloride is rapidly absorbed by all routes of expo-
sure in animals and humans, followed by wide distribution, partic-
ularly into tissues with high lipid content (EPA, 2010). Depending
on the dose and route of absorption, peak concentrations in tissues
occur within 1–6 h. Use of a vehicle slows absorption from the gas-
trointestinal tract, with oil-based vehicles retarding absorption
more than aqueous vehicles.
4.2. Metabolism of carbon tetrachloride to trichloromethyl radical by
the P450 enzyme CYP2E1 and subsequent formation of trichloromethyl
peroxy radical
Compelling evidence indicates that metabolic activation of car-
bon tetrachloride is required for toxicity (Manibusan et al., 2007;
EPA, 2010). Within the endoplasmic reticulum, CYP2E1 (and possi-
bly other cytochrome P450 iso-forms) reductively dehalogenate
carbon tetrachloride to the trichloromethyl radical, which then
combines with molecular oxygen to form the trichloromethyl per-
oxy radical. The trichloromethyl peroxy radical readily abstracts
hydrogen atoms from nearby fatty acid-containing membranes to
initiate lipid peroxidation. The signiﬁcance of CYP2E1 to carbon
tetrachloride-induced hepatotoxicity has been demonstrated
counterfactually in CYP2E1 knockout mice, which exhibit none of
the liver damage evident in wild type mice following high dose
administration (markedly increased levels of liver transaminases
in serum and signiﬁcant centrilobular liver necrosis).
4.3. Autocatalytic lipid peroxidation in organelles proximate to
trichloromethyl peroxy radical as it forms
Lipid peroxidation perturbs membranes and membrane func-
tions and inactivates proteins. However, it also sets into motion a
complex series of reactions that produce reactive oxygen species,
lipid peroxy radicals, aldehydes, and carbonyls, all of which may
alkylate DNA and proteins. The intense reactivity of the trichloro-
methyl and trichloromethyl peroxy radicals should limit these
alkylations to macromolecules close to the site of metabolism. A
number of studies corroborate that carbon tetrachloride-induced
damage begins in the endoplasmic reticulum and only later, if lipid
peroxidation is sufﬁciently widespread to deplete the high levels of
antioxidants and other hepatoprotective defense mechanisms does
damage to nuclear components occur (Eastmond, 2008;
Manibusan et al., 2007; Meek et al., 2014b). Such events are consis-
tent with high, but not with low, carbon tetrachloride doses.
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toxicity of carbon tetrachloride is the counterfactual demonstra-
tion that treatment with antioxidants is preventive (Khan et al.,
2012).
4.3.1. Lack of carbon tetrachloride genotoxicity
Eastmond (2008) conducted an extensive evaluation of the
genotoxic and mutagenic effects of carbon tetrachloride. Using a
WoE approach, he concluded that carbon tetrachloride should
not be considered a direct-acting mutagen. Across the large num-
ber of studies conducted, results are mostly negative, with the
few positive results generally occurring under conditions closely
associated with cytotoxicity or oxidative and lipid peroxidative
stress (Eastmond, 2008; Manibusan et al., 2007). Thus, if genotoxic
events occur, they are likely secondary to damage during early to
intermediate stages of apoptotic or necrotic cell death.
Conditions producing high cytotoxicity are also capable of inducing
DNA breakage and related endpoints, but these tend to be of mod-
est magnitude and are not of the type that leads to aberrant DNA
repair and subsequent mutagenic risks. Instead, genotoxicity
observed with carbon tetrachloride has been either of the type
observed in dead or dying cells, considered to be irrelevant to
mutagenic potential, or of the type that results from cytotoxicity
and would be highly unlikely to occur without cytotoxicity
(Eastmond, 2008). Thus, while theories about the involvement of
carbon tetrachloride-induced genotoxicity can never be fully dis-
proved, extensive genotoxicity and mutagenicity studies have
failed to provide evidential support. Instead, those data support
the conclusion that if such events occur, they result from cytotox-
icity and present no carcinogenic hazard without cytotoxicity.
4.4. Loss of calcium homeostasis, which activates degradative
enzymes, producing cytotoxicity
Carbon tetrachloride promotes inﬂux of calcium into the cyto-
plasm, and inhibits active transport of calcium ions out of the cyto-
plasm (Manibusan et al., 2007). Although at lower concentrations,
carbon tetrachloride can open certain calcium transport channels
in membranes, disruption of calcium homeostasis appears to result
largely from damage to membranes via lipid peroxidation.
Membranes damaged by peroxidation can release calcium from
intracellular storage compartments thereby activating proteases
and phospholipases (Manibusan et al., 2007), and can release lyso-
somal nucleases that can produce DNA breakage and fragmenta-
tion. These types of damage lead to apoptosis and necrosis, both
of which have been reported with high dose carbon tetrachloride.
Other DNA damage may also occur, such as adduct formation,
cross-linking of DNA and DNA to proteins, and double- and
single-stranded DNA breaks. Reactive species formed during lipid
peroxidation can also damage the cytoskeleton, interfere with
mitotic spindle formation and microtubule protein structure and
function, and disrupt calcium homeostasis, all of which can impair
normal chromosomal segregation during mitosis. Although these
events are consistent with a genotoxic mode of carbon tetrachlo-
ride action, they are also consistent with high-dose, but not low
dose carbon tetrachloride toxicity that produces an initial cytotoxic
insult.
4.5. Sustained regenerative cell proliferation in liver and/or kidney
Cells that are severely damaged by the above processes likely
die, but less damaged cells may begin to divide and replace the
necrotic cells (Eastmond, 2008; Manibusan et al., 2007).
Damaged cells that are not necrotic or apoptotic may contain
pre-mutagenic lesions that can be converted into mutations either
at the gene or chromosome level. Mutations in certaincancer-related genes can initiate the carcinogenic process.
Damage to microtubules and spindle proteins can disrupt normal
chromosome segregation and produce aneuploidy, which can con-
tribute to the neoplastic process. The rapid cellular proliferation
that ensues after massive hepatic necrosis increases spontaneous
and induced mutations and chromosomal alterations due to insuf-
ﬁcient time to repair damaged DNA or critical proteins. As immune
cells inﬁltrate necrotic areas to begin the process of tissue repair,
they also generate reactive oxygen and nitrogen species that can
damage DNA. Thus, carbon tetrachloride cytotoxicity that leads
to sustained cell proliferation in the liver and kidney can induce
neoplasia by increasing DNA damage and mutations and decreas-
ing cellular repair (Eastmond, 2008; Manibusan et al., 2007; EPA,
2010). However, these events would not be increased in the
absence of sustained cytotoxicity and proliferation.
4.6. Correlation of high-dose sustained cytotoxicity and regenerative
hyperplasia with development of tumors in liver
No-effect levels for liver tumors have been observed in mice
and rats and for adrenal tumors in mice (Manibusan et al., 2007).
Furthermore, current evidence indicates a non-linear relationship
between carbon tetrachloride dose and its genotoxic response in
liver, with a steep dose–response above the observable response
level (Eastmond, 2008). Modeling of tumor responses based on a
cytotoxic MoA reasonably accounts for the critical parameters,
but may slightly under-predict tumor responses at the lowest
observed response level, suggesting that cytotoxicity alone may
oversimplify the MoA (Luke et al., 2010). This seems to ﬁt with
the ancillary effects of cytotoxicity, which could serve to increase
tumor response slightly above the dose–response for cytotoxicity
once the cytotoxic threshold has been achieved, and would be
most discernible at the lowest observable tumorigenic dose.
Chronic toxicity may not only increase the number of cells contain-
ing mutations, but by overwhelming DNA-repair and inducing
regenerative proliferation, can also lead to a clonal expansion of
initiated cells, further facilitating requisite steps for the develop-
ment of liver cancer (Eastmond, 2008; Manibusan et al., 2007).
4.7. Evidence integration: WoE conclusion for carbon tetrachloride
carcinogenic hazard
The extant data regarding the carcinogenic MoA for carbon
tetrachloride (Table 2) favors hypothesis 4, indicating a cytotoxic,
threshold MoA and a lack of human carcinogenic hazard below
that threshold. Support for other hypotheses is limited and the
data are consistent with only some of the observed key events.
Although the data are consistent with a requirement for sustained
cytotoxicity and regenerative hyperplasia in the development of
liver tumors following exposure to carbon tetrachloride, there are
no counterfactually based experimental results demonstrating
the requirement for carbon tetrachloride as are available for chlo-
roform (dependency on bolus doses by gavage versus drinking
water exposures). The requirement for free radical damage occur-
ring with high but not with low doses, however, has been demon-
strated counterfactually (Khan et al., 2012), a factor that lends
considerable support for hypothesis 4. Dose response characteris-
tics would seem to be an important area to consider such experi-
mental approaches, as it is generally agreed that dose response
characteristics are important to MoA analysis and should inform
the hazard characterization, particularly when the underlying biol-
ogy indicates nonlinear processes or dose transitions (Boobis et al.,
2006).
Even though support for the default hypothesis (hypothesis 1) is
weak, at best, EPA concluded that there are ‘‘. . . insufﬁcient data at
low doses to rule out the possibility of low-dose genotoxicity or other
Table 2
Comparison of support for hypotheses regarding carbon tetrachloride carcinogenicity.
Key events in the animal MoA Hypothesis 1
Possible human carcinogen at
foreseeable exposures by
genotoxic MoA at all exposure
levels
Hypothesis 2
Unlikely human
carcinogen at foreseeable
exposures by genotoxic,
thresholded MoA
Hypothesis 3
Possible human carcinogen at
foreseeable exposures by
cytotoxic MoA at all exposure
levels
Hypothesis 4
Unlikely human
carcinogen at foreseeable
exposures by cytotoxic,
thresholded MoA
Absorption and distribution of carbon
tetrachloride to the liver (target
tissue)
Consistent Consistent Consistent Consistent
Metabolism to trichloromethyl radical by
CYP2E1 and subsequent formation of
trichloromethyl peroxy radical
Consistent Consistent Consistent Consistent
Autocatalytic lipid peroxidation in
organelles proximate to the peroxy
radical as it forms
Inconsistent Inconsistent Consistent Consistent
Lack of carbon tetrachloride genotoxicity Inconsistent Inconsistent Consistent Consistent
Loss of calcium homeostasis, which
activates degradative enzymes,
producing cytotoxicity
Inconsistent Inconsistent Inconsistent Consistent
Sustained regenerative cell proliferation
in liver and/or kidney
Inconsistent Consistent Inconsistent Supportive
Correlation of high-dose sustained
cytotoxicity and regenerative
proliferations with production of
tumors in liver and/or kidney
Inconsistent Inconsistent Consistent Supportive
, These steps are strongly supported by counterfactual demonstrations in CYP2E1 knockout mice and by reversal with administration of exogenous glutathione, but
these demonstrations do not help to distinguish the presence of a threshold.
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another) MoAs independent of cytotoxicity and regenerative cell pro-
liferation may be operative in this range’’ (EPA, 2010) in support of
its decision to use a low dose linear approach for characterizing
risks to humans and environmentally relevant levels of exposure.
Such a conclusion can only have been reached when the problem
formulation used, and decision logic employed, elevates the default
approach and assumptions to a level that they must be disproved
before an alternative hypothesis can be accepted. Since this
approach requires proving a negative, is inconsistent with scien-
tiﬁc hypothesis-testing paradigms, and leads to conclusions incon-
sistent with the experimental data, it is clear that improving the
scientiﬁc basis of hazard characterizations and risk assessments
requires modernizing problem formulation.
As was mentioned for chloroform, speculation could be raised
that the hazard identiﬁcation of carbon tetrachloride according to
hypothesis 4 – unlikely to be a human carcinogen at foreseeable
human exposure levels – is dependent on exposure assumptions
that could be exceeded under some scenarios. This, and any other
speculation, would be best addressed by a separate hypothesis in
the problem formulation phase. If considered, it would be impor-
tant to address the degree of conservatism inherent in the hazard
identiﬁcation exposure assumptions and in the regulatory toxicity
values developed for carbon tetrachloride. Because carbon tetra-
chloride is pharmacokinetically and mechanistically similar to
chloroform, it is likely that, as discussed above regarding chloro-
form, exposures well above the rodent NOAEL would be required
to produce toxicity and regenerative hyperplasia in humans. In
that light, EPA’s chronic oral reference dose (0.004 mg/kg-day) can-
cer reference dose (0.007 mg/kg-day), and cancer risk-speciﬁc dose
(0.14 mg/kg-day) are highly conservative with respect to the
sub-chronic NOAEL for rodent liver toxicity of 1 mg/kg-day.5. Criteria for accepting a MoA hypothesis
Principles and procedures for evaluating hypotheses by WoE
have been published previously (reviewed in Rhomberg et al.,2013; Meek et al., 2014; Borgert et al., 2011). Rhomberg et al.
(2013) recommend that each assessment comply with best prac-
tices for design, data acquisition, and data evaluation, which
includes the development of a protocol document prior to conduct-
ing the assessment that clearly articulates the hypotheses to be
evaluated and details of the analytical procedures to be used in
conducting the assessment. They propose evaluating speciﬁc sets
of points for each phase of the assessment to help ensure that
the evidence for and against each hypothesis can be integrated
and compared fairly by independent experts and peer-reviewers.
They conclude that in most cases, it should be possible to deter-
mine which hypothesis regarding the human carcinogenicity (or
other postulated hazard) is best supported by the data. In order
to provide a foundation for policy decisions, it would also be nec-
essary to consider whether the evidence is sufﬁcient to support
one hypothesis as the MoA upon which dose response models
and human health risk assessment should be based.
When considering sufﬁciency of support for a particular
hypothesis, emphasis should be placed on counterfactual lines of
evidence, as this is one of the most powerful approaches by which
systematic experimentation can demonstrate causal relationships.
Deemed a test of tertiary data validity by Borgert et al. (2011),
counterfactuals test whether the effect of interest still occurs when
a putative causal step is prevented under conditions that would
otherwise produce the effect. Likewise, the second WoE criterion
proposed by Meek et al. (2014a, 2014b) is ‘‘Essentiality of Key
Events’’ which asks, ‘‘Is the sequence of events reversible if dosing is
stopped or a key event prevented (i.e., counterfactual evidence)?’’
Consistent with those authors, Sonich-Mullin et al. (2001) note,
under the designation of ‘‘Strength, Consistency, and Speciﬁcity of
Association of Tumor Response with Key Events,’’ that ‘‘Stop/recovery
studies showing absence or reduction of subsequent events or tumor
when a key event is blocked or diminished are particularly important
tests of the association.’’ Other examples of counterfactual data
would include results from knock-out or knock-in models.
Because counterfactual evidence is the essential element of causal
reasoning in experimental pharmacology and toxicology (Borgert
et al., 2011), this type of evidence deserves special consideration
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ducing animal tumors.
From these methods and considerations, we propose that the
following criteria would justify and provide compelling rationale
for applying non-linear, threshold models in cancer risk assess-
ment so that policy decisions are consistent with the best available
science.
I. Deﬁned key events should be consistently (not necessarily
unanimously) supported among objective analyses.
II. Data supporting the proposed key events should be of equal
or higher quality than contradictory data.
III. The more key events that are supported by counterfactual
evidence and experiments, the stronger the support for the
overall hypothesis.
IV. The MoA should not differ by route of exposure (if a chemi-
cal’s MoA does differ by route of exposure, the MoA evalua-
tion should reﬂect those differences).
V. Alternative MoA hypotheses should be consistently ruled
out or considered unlikely among objective analyses.
6. Discussion
EPA’s recent publication ‘‘Framework for Human Health Risk
Assessment to Inform Decision Making’’ (EPA, 2014) emphasizes
the importance of planning and scoping and problem formulation
steps for improving the utility of risk assessments. As part of prob-
lem formulation, this EPA guidance calls for development of ‘‘(1) a
set of risk hypotheses that describe predicted relationships among
stressors, exposure and health endpoints and/or responses, along
with the rationale for their selection; and (2) a diagram that illus-
trates the relationships presented in the risk hypotheses.’’
However, this EPA guidance focuses on formulation of hypothe-
sized pathways of exposure and does not provide details or exam-
ples illustrating the formulation of actual MoA hypotheses for
hazard characterization or risk assessment. The approach we
describe herein, and illustrate with examples, speciﬁcally demon-
strates how development of alternative hypotheses at the problem
formulation stage can and should be carried out. As articulated, our
approach is a means for actualizing the Hypothesis-Based WoE
approach from the outset of an assessment, and is fully consistent
with EPA guidance and with the NAS 2014 report on IRIS.
Before the 1970s, the practice of toxicology was a largely obser-
vational discipline. But beginning in the 1970s and continuing to
this day, toxicology is increasingly focused on understanding the
mechanistic underpinnings, both dynamics and kinetics, leading
to manifestations of toxicity. Yet, despite more than 30 years of
extensive mechanistic toxicological research by academia, research
institutions and the private sector, many regulatory programs con-
tinue to rely on default approaches for hazard characterizations
and risk assessments that date back to the 1970s. Even though
frameworks for integrating mechanistic information have been
developed by authoritative bodies (IPCS/HRF), and similar
approaches have been incorporated into the EPA cancer guidelines
(EPA, 2005), at the present time, there is uneven use of such
approaches in hazard characterizations and risk assessments. For
example, on numerous occasions, EPA’s Ofﬁce of Pesticide
Programs has reached conclusions, based on consideration of
MoA and human relevance, that carcinogenic effects in animal
studies are not relevant to humans or the carcinogenic effects are
secondary to target organ toxicity, and thus no carcinogenic risks
are posed to humans at does below those which produce such tox-
icities (see Supplemental Material for separate list of references).
However, within the same Agency, the IRIS program, as evidenced
by the carbon tetrachloride example, continues to rely on the
1970s default approach and a decision logic that elevates thedefault hypothesis to such a level that requires that an unattain-
able level of evidence be provided – essentially, that default
assumptions unveriﬁed by data, ﬁrst be disproved – before an
alternative hypothesis can be accepted. On its face, this latter
approach may seem to some to be both scientiﬁcally-based and
appropriate policy. However, it clearly is not. The approach can
be used selectively rather than scientiﬁcally, e.g., in the case of car-
bon tetrachloride, to argue that even a large body of data to the
contrary is insufﬁcient to assure absence of the default, for which
no supporting data are deemed necessary. In the face of over-
whelming WoE that there is no mutagenic MoA operating at low,
environmentally relevant exposures to carbon tetrachloride, EPA
IRIS used precisely this argumentation to justify an Agency deci-
sion to use linear low dose extrapolation for human health risk
evaluations.
Understanding, acting upon and communicating potential risks
is made considerably more difﬁcult by codifying problem formula-
tion according to default assumptions, only to be reﬁned or in
some cases, corrected, by modern understanding of mechanisms
of toxicity, toxicokinetics and human relevance. Contradictory
messages can be conveyed when chemicals are interpreted as
human carcinogenic hazards, only to be declared to pose no car-
cinogenic risk because the means by which they cause cancer can-
not occur because of species differences in speciﬁcities or because
modes of action related to tumor induction in animal studies are
not possible at environmentally relevant human exposure levels.
With such illogical statements about the risk posed by exposure
to trace levels of chemicals, it should come as no surprise that pub-
lic misunderstanding and skepticism is widespread.
These and other problems can be lessened considerably by
ensuring that the problem formulation phase of risk assessment
poses questions directly relevant to humans by considering alter-
nate modes of action in developing the hazard and risk questions.
Formulating and comparing the evidence to support competing
hypotheses about human hazard more closely aligns the risk
assessment process with the hypothesis testing paradigm of phar-
macological and toxicological sciences. Since these sciences pro-
vide the foundational data for human risk assessment, this
realignment should serve to strengthen the theoretical as well as
the empirical basis for risk assessment.Conﬂict of interest
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